Critical Care Injection Franchise in Ahmedabad

CU Injection Supplier in Mumbai

Critical Care Medicine Distributor in Delhi

Ulinastatin Injection Manufacturer in Bangalore

Pharma Injection Stockist in Hyderabad
Critical Care Injection Exporter in Chandigarh

Home/Products /ulinastatin-100000iu-injection

Ulinate Injection

Composition : Ulinastatin (100000IU)

Dosage Form : Injection

Packaging Type : Vial

Packaging : mono

Price : ₹1/-

Ulinate Injection contains Ulinastatin 100000 IU, a protease inhibitor used in the treatment of acute pancreatitis, sepsis, and various inflammatory conditions. It plays a key role in reducing inflammation and preventing tissue damage in critical conditions.

Ulinastatin works by inhibiting harmful enzymes such as trypsin and other proteases, which are responsible for inflammation and organ damage. This helps in controlling systemic inflammatory response and improves patient outcomes in severe conditions.

This injection is widely used in intensive care units (ICU) and hospital settings for managing critically ill patients. Its effectiveness in reducing complications and supporting recovery makes it a valuable component in critical care treatment protocols.

With growing demand in critical care management and increasing ICU admissions, this product offers strong market potential. Its high-value segment, hospital-based usage, and consistent requirement make it a strategic product for business growth in the critical care segment.


Read More

About the Product

Ulinate Injection contains Ulinastatin 100000 IU, a protease inhibitor used in the treatment of acute pancreatitis, sepsis, and various inflammatory conditions. It plays a key role in reducing inflammation and preventing tissue damage in critical conditions.

Ulinastatin works by inhibiting harmful enzymes such as trypsin and other proteases, which are responsible for inflammation and organ damage. This helps in controlling systemic inflammatory response and improves patient outcomes in severe conditions.

This injection is widely used in intensive care units (ICU) and hospital settings for managing critically ill patients. Its effectiveness in reducing complications and supporting recovery makes it a valuable component in critical care treatment protocols.

With growing demand in critical care management and increasing ICU admissions, this product offers strong market potential. Its high-value segment, hospital-based usage, and consistent requirement make it a strategic product for business growth in the critical care segment.


Common side effects may include pain or irritation at the injection site, nausea, vomiting, diarrhea, and skin rash. Some patients may experience allergic reactions or elevated liver enzymes. Rarely, severe hypersensitivity reactions or blood-related disorders may occur.

Ceftizoxime 1 gm Injection is indicated for the treatment of a wide range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and bone and joint infections. It is a third-generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis.

This medication should be used under medical supervision. Inform your doctor if you have a history of allergy to cephalosporins or penicillins. Complete the full prescribed course to avoid antibiotic resistance. Use with caution in patients with kidney impairment.

Store in a cool, dry place below 25°C. Protect from light and moisture. Keep in original packaging and out of reach of children. Use as directed after reconstitution.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation